iSpecimen Inc. Proceeds from Sale of Debt Securities, Available-for-sale
iSpecimen Inc. (ISPC) reported Proceeds from Sale of Debt Securities, Available-for-sale of $7.35 million for the 9-month period ending 2023-09-30, per its 10-Q filed 2023-11-02.
Discontinued › Cash Flow
us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt · last filed 2023-11-02
- iSpecimen Inc. proceeds from sale of debt securities, available-for-sale for the quarter ending 2023-09-30 was $5.82M.
| Period end | Proceeds from Sale of Debt Securities, Available-for-sale 3 month | Proceeds from Sale of Debt Securities, Available-for-sale 6 month | Proceeds from Sale of Debt Securities, Available-for-sale 9 month |
|---|---|---|---|
| 2023-09-30 | $5.82M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $7.35M 10-Q · filed 2023-11-02 | |
| 2023-06-30 | $1.53M 10-Q · filed 2023-08-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| OneMedNet Corp (ONMD) | $0.042B | ||
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |